
Compass Therapeutics
Biotechnology • Boston, MA
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company that develops antibody-based therapeutics for cancer and other serious diseases. Its pipeline includes tovecimig (CTX-009), a bispecific antibody that targets DLL4 and VEGF-A. It is being studied in biliary tract cancer. Its other programs include CTX-471, a CD137 agonist antibody, and CTX-8371, a PD-1xPD-L1 bispecific antibody.


